RSC Advances
Page 4 of 4
DOI: 10.1039/C4RA05405A
5765–5780; (d) C. L. Elston, R. F. W. Jackson, S. J. F. MacDonald,
P. J. Murray, Angew. Chem. Int. Ed. Engl., 1997, 36, 410–412;
Angew. Chem., 1997, 109, 379–381.
3
(a) C. Rosini, L. Franzini, D. Pini, P. Salvadori, Tetrahedron:
Asymmetry, 1990, 1, 587–588; (b) P. N. Devine, T. Oh, J. Org.
Chem., 1992, 57, 396–399; (c) K. R. K. Prasad, N. N. Joshi,
Tetrahedron: Asymmetry, 1996, 7, 1957–1960; (d) K. Ishihara, D.
Nakashima, Y. Hiraiwa, H. Yamamoto, J. Am. Chem. Soc., 2003,
125, 24–25.
5
10
15
20
25
30
35
40
45
4
5
(a) D. Seebach, A. K. Beck, A. Heckel, Angew. Chem. Int. Ed., 2001,
40, 92–138; Angew. Chem., 2001, 113, 96–142; (b) H. Pellissier,
Tetrahedron, 2008, 64, 10279–10317.
For selected reviews of BINOL, see: (a) J. M. Brunel, Chem. Rev.,
2005, 105, 857–897; (b) M. Shibasaki, S. Matsunaga, in Privileged
Chiral Ligands and Catalysts, ed. Q.–L. Zhou, WILEY–VCH,
Weinheim, 2011, ch. 8, pp. 295–332.
A. K. Unni, N. Takenaka, H. Yamamoto, V. H. Rawal, J. Am. Chem.
Soc., 2005, 127, 1336–1337.
(a) K. Matsuo, K. Tanaka, Yakugaku Zasshi, 1984, 104, 1004–1008;
(b) M. J. Begley, N. G. Clemo, G. Pattenden, J. Chem. Soc. Perkin
Tarans. 1, 1985, 2393–2397; c) K. Gorlitzer, J. Trittmacher, U.
Bartke, Pharmazie, 2002, 57, 606–609.
For examples of acidꢀcatalyzed condensation giving 1,3–diketones
(ene–diones) 4, see: (a) H. G. Henning, A. Koppe, S. Briehn,
Pharmazie, 1988, 43, 473–474; (b) M. N. S. Saudi, M. M. A. El
Semary, G. El Sawaf, Pharmazie, 2002, 57, 519–522; (c) C. A.
Holloway, C. J. Matthews, Y.–C. Jeong, M. G. Moloney, C. F.
Roberts, M. Yaqoob, Chem. Biol. Drug. Des., 2011, 78, 229–235.
(a) B. J. L. Royles, Chem. Rev., 1995, 95, 1981ꢀ2001; (b) R.
Schobert, A. Schlenk, Bioorg. Med. Chem., 2008, 16, 4203–4221.
6
7
8
9
10 (a) S. V. Ley, S. C. Smith, P. R. Woodward, Tetrahedron, 1992, 48,
1145–1174; (b) T. Sengoku, Y. Nagae, Y. Ujihara, M. Takahashi, H.
Yoda, J. Org. Chem., 2012, 77, 4391–4401.
11 As expected, racemic proline gave results very comparable to those
with L–proline.
12 (a) Y. Oikawa, H. Hirasawa, O. Yonemitsu, Chem. Pharm. Bull.,
1982, 30, 3092–3096; (b) B. List, C. Castello, Synlett, 2001, 1687–
1689; (c) G. Cardillo, S. Fabbroni, L. Gentilucci, M. Gianotti, A.
Tolomelli, Synth. Commun., 2003, 33, 1587–1594; (d) A. Lee, A.
Michrowska, S. Sulzer–Mosse, B. List, Angew. Chem. Int. Ed., 2011,
50, 1707–1710; Angew. Chem., 2011, 123, 1745–1748.
13 (a) N. Halland, T. Hansen, K. A. Jørgensen, Angew. Chem. Int. Ed.,
2003, 42, 4955–4957; Angew. Chem., 2003, 115, 5105–5107; (b) A.–
B. Xia, D.–Q. Xu, S.–P. Luo, J.–R. Jiang, J. Tang, Y.–F. Wang, Z.–
Y. Xu, Chem. Eur. J., 2010, 16, 801–804; (c) N. C. Ganguly, S. Roy,
P. Mondal, R. Saha, Tetrahedron Lett., 2012, 53, 7067–7071.
14 The product ratio, cis–/trans–isomers, was not determined because
the observed 1H NMR data for the isomeric mixture of the ene–dione
are essentially indistinguishable from each other.
50 15 Crystal data for 3g: orthorhombic, space group P212121,
10.4426(6) Å, b = 12.0149(7) Å, c = 21.1390(13) Å, V = 2652.2(3)
Å3, Z = 4, = 1.359 Mgmꢀ3, (CuKα) = 0.809 mmꢀ1, T = 173 K; in the
final least–squares refinement cycles on F2, the model converged at
R1 = 0.1071 (I > 2 (I)), wR2 = 0.2861, and GOF = 1.107 for 4427
a =
ρ
ꢀ
ρ
55
reflections and 367 parameters (CCDC deposition number 963494).
16 The elemental analysis data of 3g (C, 65.90; H, 5.13; N, 8.12) are in
good agreement with the calculated values for C29H25N3O6·CH3OH
(C, 66.29; H, 5.38; N, 7.73).
17 The O(3)•••HO(6) bond length is estimated to be 1.93 Å.
60 18 S. Paliwai, S. Geib, C. S. Wilcox, J. Am. Chem. Soc., 1996, 116,
4497–4498.
4
| Journal Name, [year], [vol], 00–00
This journal is © The Royal Society of Chemistry [year]